ArticleJournal of cachexia, sarcopenia and muscle2021
The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab.
Article in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis.Frontiers in immunology · 2026Pooled it
- Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis.Scientific reports · 2024Pooled it
- Imaging-based adipose biomarkers for predicting clinical outcomes of cancer patients treated with immune checkpoint inhibitors: a systematic review.Frontiers in oncology · 2023Pooled it
- A Review of the Relationship Between Obesity and Immunotherapy Response in Cancer.International journal of molecular sciences · 2026Review
- Longitudinal PET/CT-Derived Body Composition Changes During Systemic Therapy in Patients with Lung Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Longitudinal computed tomography body composition changes in patients receiving curative radiotherapy for non-small cell lung cancer.Physics and imaging in radiation oncology · 2026Article
- Combination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.Journal of cardiovascular development and disease · 2026Article
- Impact of baseline nutritional and inflammatory markers on safety and efficacy of immune checkpoint inhibitors in cancer patients: a retrospective, monocentric study.Discover oncology · 2026Article
- Impact of combined skeletal muscle index, subcutaneous fat index, and visceral fat index on prognosis in non-metastatic non-small cell lung cancer.BMC pulmonary medicine · 2026Observational
- When adipose meets inflammation: a novel adiposity-inflammation signature predicts prognosis and chemotherapy benefit in locally advanced gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- CT Body Composition Changes Predict Survival in Immunotherapy-Treated Cancer Patients: A Retrospective Cohort Study.Cancers · 2026Article
- Prevalence and Development of Cachexia Before and After Diagnosis of Non-small Cell Lung Cancer.American journal of clinical oncology · 2025Article
- Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.Cancers · 2024Article
- Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.Journal of cachexia, sarcopenia and muscle · 2024Article
- Construction and validation of deep learning model for cachexia in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors: a multicenter study.Translational lung cancer research · 2024Article
- Targeted nutritional intervention attenuates experimental lung cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2024Article
- Severe weight loss during PD-1 treatment is a risk sign of poor prognosis for advanced GC patients.International journal of clinical oncology · 2024Article
- Influence of cachexia on immunotherapy efficacy and prognosis for malignant tumors of the digestive system.Cancer reports (Hoboken, N.J.) · 2024Article
- Correlation between changes in nutritional status and tumor response in patients receiving immunotherapy for lung cancer (NUTIMMUNO study).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is not well known to what extent effectiveness of treatment with immune checkpoint inhibitors in stage IV non-small-cell lung cancer (NSCLC) is influenced by weight loss and changes in body composition. Therefore, the goal of this study was to evaluate body composition changes in relation to early weight change and overall survival (OS) in stage IV NSCLC patients treated with second-line nivolumab.
methodsAll patients with stage IV NSCLC, who were treated with second-line nivolumab between June 2015 and December 2018 at Maastricht University Medical Center, were evaluated. Skeletal muscle mass (SMM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were assessed at the first lumbar level on computed tomography images obtained before initiation of nivolumab and at week 6 of treatment. The contribution of changes in body weight (defined as >2% loss), SMM, VAT, and SAT to OS was analysed by Kaplan-Meier method and adjusted for clinical confounders in a Cox regression analysis. The results from the study cohort were validated in another Dutch cohort from Erasmus Medical Center, Rotterdam.
resultsOne hundred and six patients were included in the study cohort. Loss of body weight of >2% at week 6 was an independent predictor for poor OS (hazard ratio 2.39, 95% confidence interval 1.51-3.79, P < 0.001) when adjusted for gender, >1 organ with metastasis, pretreatment hypoalbumenaemia, and pretreatment elevated C-reactive protein. The result was confirmed in the validation cohort (N = 62). Loss of SMM as a feature of cancer cachexia did not significantly predict OS in both cohorts. Significant (>2%) weight loss during treatment was reflected by a significant loss of VAT and SAT, while loss of SMM was comparable between weight-stable and weight-losing patients.
conclusionsWeight loss, characterized by loss of subcutaneous and visceral adipose tissues, at week 6 of treatment with nivolumab, is a significant poor prognostic factor for survival in patients with Stage IV NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.